The URL can be used to link to this page

Home My WebLink About10.05.25 Board Correspondence - FW_ DARE-SAFE_ A New Standard for Comparing Vaccine and Drug Safety.ATTENTION: This message originated from outside Butte County. Please exercise judgment before opening attachments, clicking on links, or replying.. From:Clerk of the Board To:Mutony, Heather Cc:Lee, Lewis Subject:Board Correspondence - FW: DARE-SAFE: A New Standard for Comparing Vaccine and Drug Safety Date:Monday, October 6, 2025 9:07:00 AM Please see Board Correspondence - From: lance dreiss <lancedreiss@att.net> Sent: Sunday, October 5, 2025 10:01 AM To: Shared Mailbox Clerk of the Board <pcbs@countyofplumas.com>; Soderstrom, Monica <msoderstrom@buttecounty.net>; Assemblymember.Gallagher@assembly.ca.gov; Senator.Dahle@senate.ca.gov; davidhollister@countyofplumas.com; sheriff@countyofplumas.com; District Attorney <DA@buttecounty.net>; Kimmelshue, Tod <TKimmelshue@buttecounty.net>; Pickett, Andy <APickett@buttecounty.net>; Connelly, Bill <BConnelly@buttecounty.net>; Teeter, Doug <DTeeter@buttecounty.net>; Julie Threet <julie4butte5@gmail.com>; Waugh, Melanie <mwaugh@buttecounty.net>; Kitts, Melissa <mkitts@buttecounty.net>; Durfee, Peter <pdurfee@buttecounty.net>; Ritter, Tami <TRitter@buttecounty.net>; Teri DuBose <Teri.DuBose@mail.house.gov>; Congressman Doug LaMalfa <CA01DL.Outreach@mail.house.gov>; Stephens, Brad J. <BStephens@buttecounty.net>; Clerk of the Board <ClerkoftheBoard@buttecounty.net> Subject: Fwd: DARE-SAFE: A New Standard for Comparing Vaccine and Drug Safety Public Record “The rollout of the COVID-19 mRNA vaccines pushed the issue into the spotlight. Suddenly,even those who had never questioned vaccine safety began asking why adverse eventswere being ignored, denied, or dismissed.” diana dreiss Begin forwarded message: From: Independent Medical Alliance <imahealth@substack.com> Date: October 5, 2025 at 9:31:33 AM PDT To: lancedreiss@att.net Subject: DARE-SAFE: A New Standard for Comparing Vaccine and Drug Safety Reply-To: Independent Medical Alliance <reply+2wdsgf&kcryl&&7ab4608ea3813a12ffbc0053a201baec8a72a738e4eea4373f5a 2585afb6a906@mg1.substack.com> A new study from IMA researchers introduces DARE-SAFE, a first-of-its-kind system for vaccine and drug safety—showing COVID-19 vaccines had 63x higher reported death rates than flu shots.͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ Forwarded this email? Subscribe here for more DARE-SAFE: A New Standard forComparing Vaccine and Drug Safety A new study from IMA researchers introduces DARE-SAFE, a first-of-its- kind system for vaccine and drug safety—showing COVID-19 vaccines had 63x higher reported death rates than flu shots. INDEPENDENT MEDICAL ALLIANCE OCT 5 READ IN APP DARE-SAFE study hero image No matter where you stand on vaccines, one thing is hard to ignore: there’s a serious safety data problem. For decades, pharmacovigilance systems like the Vaccine Adverse Event Reporting System (VAERS) and the FDA Adverse Event Reporting System (FAERS) have struggled to provide reliable comparisons between drugs or detect meaningful safety signals. Organizations like Children’s Health Defense have documented these failures for years. The rollout of the COVID-19 mRNA vaccines pushed the issue into the spotlight. Suddenly, even those who had never questioned vaccine safety began asking why adverse events were being ignored, denied, or dismissed. Now, IMA researchers Matt Halma and Dr. Joseph Varon have teamed up to create a tool that confronts this problem directly. The DARE-SAFE method— short for Denominator-Adjusted Rate Estimates of Substance Adverse Events Frequency Evaluation—is the first comparison of adverse event reporting rates across different vaccines and pharmaceuticals. DARE-SAFE: Denominator-Adjusted Rate Estimates of Substance Adverse Events Frequency Evaluation in Pharmaceuticals and Vaccines – Matt Halma, Joseph Varon Download the PDF What the DARE-SAFE Method Measures The goal of DARE-SAFE is simple: to standardize how we evaluate adverse event reports. The method tackles the biggest weakness of passive surveillance systems: the lack of denominator data. It achieves this by incorporating dose and Researchers used: OpenVAERS and CDC dose data for vaccines (2006–2022) FAERS reports and ClinCalc prescription data for the top 250 drugs (2022) By analyzing both vaccines and the top 250 most commonly prescribed drugs, the method establishes baselines for what “normal” reporting patterns look like. Now, for the first time, you can compare a vaccine’s reporting rate against these baselines to see if it’s within expected ranges or signaling something unusual. The result: DARE-SAFE is a standardized, dynamic system that quantifies reports per dose and identifies when products deviate from established patterns. Explore Our Independent Research Hub From vaccine safety and cancer care to post-COVID protocols and chronic disease, our research team and senior fellows are producing science that challenges the status quo. The Research Hub is where you’ll find all our published studies, reviews, and groundbreaking monographs, all organized, accessible, and free to the public. Visit the Research Hub Key Findings From the Study This study delivers a powerful one-two punch for science: it not only introduces the DARE-SAFE system to fix a long-ignored flaw in pharmacovigilance but also uses it to reveal striking disparities in vaccine and drug safety reporting. Vaccines: COVID-19 vaccines showed 63x more VAERS death reports per dose than flu vaccines. They also exhibited nearly 19x more total adverse event reports per dose. Pharmaceuticals: While the COVID vaccine results are the most dramatic, the pharmaceutical findings also play an important role. By applying the same DARE-SAFE method to the top 250 most prescribed drugs in the U.S., the researchers were able to establish a consistent pattern of reporting: roughly 26 adverse event reports for every death report. That consistency helps set a benchmark for what “normal” looks like in post- market surveillance—something that regulators have overlooked for decades. Table 3 below shows AE rates and deaths for the ten most commonly prescribed prescription drugs in the USA. In contrast, the COVID-19 vaccine reporting ratios weren’t just higher; they were in a different universe. Without the pharmaceutical data, that distinction would be harder to see. And, as Table 2 shows below, there are even major differences in outcomes even when comparing different COVID injections: table 3 DARE-SAFE study Why This Matters The current post-market safety landscape relies heavily on incomplete data and inconsistent reporting. With DARE-SAFE, regulators and researchers finally have a way to standardize safety comparisons using real-world surveillance data. This method gives healthcare professionals and the public: A clear benchmark for comparing products A tool for detecting anomalies in safety signals A framework to evaluate post-market safety without requiring full clinical trials And unlike incidence estimates, these reporting rates reflect what’s being flagged by the public and clinicians—not what’s being estimated by models. What Happens Next The study authors are calling for further refinement of DARE-SAFE and broader application across pharmacovigilance efforts. This includes: Adapting the model for new vaccines and drug approvals Applying the framework to international surveillance systems Integrating the method into ongoing regulatory oversight The Independent Medical Alliance plans to continue supporting data transparency and safety science through ongoing analysis and collaboration. Too many studies stay buried in academic journals. We believe research like this deserves a public spotlight—especially when it offers solutions to long-standing safety concerns. The data is here. The patterns are clear. And now, with a standardized method, there’s no excuse not to act. This is the kind of scientific work that empowers patients, challenges regulatory complacency, and restores integrity to public health decision-making. It’s also the kind of donor-supported research that drives our mission forward. With each peer-reviewed study, we move one step closer to a world where practitioners and patients have the data they need to make truly informed decisions. Explore more of our original research and breakthrough studies below: Nature’s Overlooked Osteoporosis Solution: New Study Finds Up to 6% Bone Density Gains Feeling Anxious? New Study Shows Ashwagandha, CBD, and Saffron Effective for Anxiety Disorders Tainted Vials: New Study Reveals Massive DNA Contamination in COVID Shots New Peer-Reviewed Study Asks: Were COVID Injections Engineered to Harm? Hybrid Harms: When COVID Shots and Infections Compound Fund Research That Changes Lives Research like this doesn’t happen overnight. Our team of dedicated experts— physicians, researchers, and clinicians—invest countless hours reviewing evidence, conducting studies, and translating complex findings into practical guidance that patients and practitioners can actually use. From breakthrough natural treatments for anxiety to innovative cancer care protocols, we’re committed to expanding the toolkit of safe, effective health solutions. Your support enables our experts to continue this vital work, ensuring that evidence-based alternatives reach the people who need them most. Support Life-Changing Research SUBSCRIBE and FOLLOW: Subscribe to our Substack Subscribe to our weekly newsletter Follow us on Facebook Follow us on Twitter (X) Follow us on Instagram Donate to our cause Subscribed LIKE COMMENT RESTACK © 2025 Independent Medical Alliance 2001 L St NW, Suite 500, Washington, DC 20036 Unsubscribe